📰 Priority Review News
Page 55 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
June 1, 2023
Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
June 1, 2023
/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune...
May 31, 2023
The company received approval for a biologics license application for an advanced melanoma therapy.
May 31, 2023
The FDA has accepted for Priority Review the NDA for repotrectinib to treat patients with ROS1-positive locally advanced or metastatic NSCLC.
May 31, 2023
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...
May 31, 2023
Iovance Biotherapeutics (NASDAQ:IOVA) told investors that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for...
May 31, 2023
Repotrectinib is a promising next-generation tyrosine kinase inhibitor under investigation for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer.
May 30, 2023
Application based on results from the registrational TRIDENT-1 trial, in which repotrectinib demonstrated high response rates and durable responses in patients with ROS1-positive locally advanced or... | May 30, 2023
May 30, 2023
STAMFORD, Conn., May 30, 2023 -- SpringWorks Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and... | May 30, 2023
May 30, 2023
The FDA has granted priority review to repotrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer.